Nav: Home

Homogeneous BTK occupancy assay

July 17, 2018

In a new SLAS Discovery article, Helen Yu and a team of researchers at Gilead Sciences, Inc. (Foster City, CA, USA) present a time-resolved fluorescence resonance energy transfer-based Bruton's tyrosine kinase (BTK) occupancy assay that can measure target engagement in peripheral blood mononuclear cells (PBMCs) and in lymph-node and bone-marrow samples. The assay provides accurate, quantitative assessment of BTK occupancy and currently is in use in ongoing tirabrutinib clinical studies.

The homogenous BTK occupancy assay's multiplexed format allows simultaneous measurement of tirabrutinib bound and total BTK levels, reducing clinical sample requirements and avoiding sampling variability observed with traditional single analyte assays.

Yu et al. take advantage of the dual wavelength emission of terbium conjugated anti-BTK antibody to serve as the energy donor for two fluorescent energy acceptors with distinct excitation and emission spectra: G2-streptavidin-bound biotinylated tirabrutinib (detects free BTK) and D2-coupled second anti-BTK antibody that binds to a different BTK epitope (detects total BTK). Additionally, the use of a common fluorescence donor serves to normalize the detection of total and free BTK with respect to each other. The assay is characterized and quantified using full-length purified recombinant human BTK protein and PBMCs derived from healthy volunteers and patients with CLL. The authors demonstrate the assay's utility using cells derived from samples from patients with CLL and DLBCL.

BTK is expressed in B cells and myeloid cells and plays an essential role in the B-cell receptor (BCR) signaling pathway. Tirabrutinib (GS-4059/ONO-4059) is a second-generation, potent, selective, irreversible BTK inhibitor. It is currently in clinical development as a treatment for chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and other lymphoid malignancies.

Integrated drug discovery and clinical development programs increasingly emphasize target engagement as a translational approach to inform pharmacodynamic and efficacy assessments. Correlation of tirabrutinib target engagement at the molecular level with pharmacological and phenotypic disease observations is crucial for establishing the appropriate clinical doses.
-end-
"Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement" can be accessed for free at http://journals.sagepub.com/doi/full/10.1177/2472555218786165. For more information about SLAS and its journals, visit http://www.slas.org/journals.

A PDF of this article is available to credentialed media outlets upon request. Contact nhallock@slas.org.

About our Society and Journals

SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).

SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).

Follow SLAS on Twitter at @SLAS_Org.

Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.

Follow SLAS on YouTube at SLASvideo.

Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).

Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).

SLAS (Society for Laboratory Automation and Screening)

Related Signaling Pathway Articles:

A new signaling pathway for mTor-dependent cell growth
A team led by the scientist Volker Haucke (Leibniz - Forschungsinstitut für Molekulare Pharmakologie and Freie Universität Berlin) has now discovered how inactivation of a certain lipid kinase promotes mTor complex 1 activity, and may therefore constitute a new point of attack for the treatment of diabetes and cancer.
Chemical probe can regulate signaling pathway and block cell invasion by arboviruses
Dysregulation of the signaling pathway known as the beta-catenin-dependent Wnt can also cause embryo malformation and contribute for the development of breast and cervical cancer.
Embryos' signaling proteins go with the flow
Protein signaling in the rapidly differentiating cells of embryos is far more complex than previously thought, as pathways take cues from many other players.
Important signaling pathway in breast cancer revealed
Researchers at Kanazawa University report in Proceedings of the National Academy of Sciences of the United States of America (PNAS) that a particular signaling pathway in breast-cancer tumors causes cancer cells to divide symmetrically, expanding the tumor.
Colon signaling pathway key to inflammatory bowel disease
Inflammatory bowel disease (IBD) develops because of an uncontrolled immune response in the colon.
More Signaling Pathway News and Signaling Pathway Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...